Carboplatin
Carboplatin (carboplatin) is a small molecule pharmaceutical. Carboplatin was first approved as Paraplatin on 1989-03-03. It is used to treat bone marrow diseases, breast neoplasms, central nervous system neoplasms, endometrial neoplasms, and esophageal neoplasms amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Carboplatin (discontinued: Carboplatin, Paraplatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carboplatin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PARAPLATIN | CordenPharma | N-019880 DISCN | 1989-03-03 | 3 products, RLD |
| PARAPLATIN | CordenPharma | N-020452 DISCN | 2003-07-14 | 4 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| carboplatin | ANDA | 2025-05-23 |
| paraplatin | ANDA | 2022-08-19 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9045 | Injection, carboplatin, 50 mg |
Clinical
Clinical Trials
3925 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 2 | — | — | 2 |
| Mucinous adenocarcinoma | D002288 | — | — | — | 1 | 2 | — | — | 2 |
| Ductal carcinoma breast | D018270 | — | — | — | 1 | 2 | — | — | 2 |
| Inflammatory breast neoplasms | D058922 | — | — | — | 1 | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 1 | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | — | 1 | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | — | 1 | — | — | — | 1 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | — | 1 | — | — | — | 1 |
| Preleukemia | D011289 | — | — | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carboplatin |
| INN | carboplatin |
| Description | Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
|
| Classification | Small molecule |
| Drug class | antineoplastics (platinum derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 41575-94-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1351 |
| ChEBI ID | 31355 |
| PubChem CID | 10339178 |
| DrugBank | DB00958 |
| UNII ID | BG3F62OND5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 84,905 documents
View more details
Safety
Black-box Warning
Black-box warning for: Carboplatin, Paraplatin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
102,962 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use